Ülke: ABD
Dil: İngilizce
Kaynak: NLM (National Library of Medicine)
LITHIUM CARBONATE (UNII: 2BMD2GNA4V) (LITHIUM CATION - UNII:8H8Z5UER66)
McKesson Corporation
LITHIUM CARBONATE
LITHIUM CARBONATE 300 mg
ORAL
PRESCRIPTION DRUG
Lithium is indicated in the treatment of manic episodes of Bipolar Disorder. Bipolar Disorder, Manic (DSM-III) is equivalent to Manic Depressive illness, Manic, in the older DSM-II terminology. Lithium is also indicated as a maintenance treatment for individuals with a diagnosis of Bipolar Disorder. Maintenance therapy reduces the frequency of manic episodes and diminishes the intensity of those episodes which may occur. Typical symptoms of mania include pressure of speech, motor hyperactivity, reduced need for sleep, flight of ideas, grandiosity, elation, poor judgment, aggressiveness, and possibly hostility. When given to a patient experiencing a manic episode, lithium may produce a normalization of symptomatology within 1 to 3 weeks. Lithium should generally not be given to patients with significant renal or cardiovascular disease, severe debilitation or dehydration, or sodium depletion, and to patients receiving diuretics, since the risk of lithium toxicity is very high in such patients. If the psychiatri
Lithium Carbonate Capsules USP, 300 mg are supplied as No. 1 Grey/Yellow Opaque Hard Gelatin Capsules Printed "West-ward 3189" in Black Ink and are available in: Boxes of UD100 NDC 63739-265-10 Store at 20-25°C (68-77°F) [See USP Controlled Room Temperature]. Protect from light and moisture. Dispense in a tight, light-resistant container as defined in the USP using a child-resistant closure. Manufactured By: West-ward Pharmaceutical Corp. 401 Industrial Way West Eatontown, NJ 07724 Distributed by: McKesson Packaging Services a business unit of McKesson Corporation 7101 Weddington Rd., Concord, NC 28027 IS-4001892-R4 July 2011
Abbreviated New Drug Application
LITHIUM CARBONATE- LITHIUM CARBONATE CAPSULE MCKESSON CORPORATION ---------- LITHIUM CARBONATE CAPSULES, USP RX ONLY WARNING Lithium toxicity is closely related to serum lithium levels, and can occur at doses close to therapeutic levels. Facilities for prompt and accurate serum lithium determinations should be available before initiating therapy. (see DOSAGE AND ADMINISTRATION). DESCRIPTION Each capsule for oral administration contains 150 mg, 300 mg or 600 mg of lithium carbonate. In addition, each capsule contains the following inactive ingredient: 150 mg: Talc. 300 mg: Talc. 600 mg: Colloidal Silicon Dioxide, Stearic Acid and Talc. Capsule shell for the 150 mg potency contains: Gelatin and Titanium Dioxide. Capsule shell for the 300 mg potency contains: D&C Yellow #10, FD&C Green #3, FD&C Red #40, FD&C Yellow #6, Gelatin and Titanium Dioxide. Capsule shell for the 600 mg potency contains: Titanium Dioxide, Gelatin and FD&C Red #40. The printing ink contains: D&C Yellow #10, FD&C Blue #1, FD&C Blue #2, FD&C Red #40, n-Butyl Alcohol, Pharmaceutical Glaze, Propylene Glycol, SDA-3A Alcohol, and Synthetic Black Iron Oxide. Lithium is an element of the alkali-metal group with atomic number 3, atomic weight 6.94 and an emission line at 671 nm on the flame photometer. Lithium Carbonate is a white, light, alkaline powder with molecular formula Li CO and molecular weight 73.89. CLINICAL PHARMACOLOGY Preclinical studies have shown that lithium alters sodium transport in nerve and muscle cells and effects a shift toward intraneuronal metabolism of catecholamines, but the specific biochemical mechanism of lithium action in mania is unknown. INDICATIONS AND USAGE Lithium is indicated in the treatment of manic episodes of Bipolar Disorder. Bipolar Disorder, Manic (DSM-III) is equivalent to Manic Depressive illness, Manic, in the older DSM-II terminology. Lithium is also indicated as a maintenance treatment for individuals with a diagnosis of Bipolar Disorder. Maintenance therapy reduces the frequency of manic episodes and di Belgenin tamamını okuyun